“We’re very excited to be making our official debut at the Greater New York Dental Meeting,” said Stephen M. Swanick, CEO and founder of PeriRx, LLC. “We’re using a variety of ways to engage with members of the dental community and tell them about SaliMark OSCC, the most clinically advanced salivary test for oral cancer, which is scheduled to ship before the end of the year.”
Development of this simple-to-use, painless, and accurate test was based on the strong scientific foundation of NIH-funded research with initial discovery and prevalidation work conducted by Dr. David Wong of the University of California at Los Angeles. What’s more, more than a decade of National Institute of Dental and Craniofacial Research and National Institute of Health-supported research make SaliMark OSCC the world’s most scientifically validated molecular DNA biomarker test for oral squamous cell carcinoma.
In addition to exhibiting at booth No. 1506, PeriRx will be introducing SaliMark OSCC in the following ways:
• Free CE course: “Salivary Testing for Early Diagnosis of Oral Cancer" (course code No. 3240) will be given on Sunday, November 30th, 2014, at 9 a.m. Attendees will receive $15 lunch voucher at the end of the course that can be used at any Javits restaurant. Course presenters are Jack Martin, MD, Neil Gottherer, DDS, and Mark Cohen, DDS. Click here to register for Free CE course.
• Free industry reception: This press conference for the entire industry will feature some late-breaking research data presented by the PeriRx executive team that further confirms the efficacy of SaliMark OSCC for early oral cancer detection. Several other industry leaders are expected to say a few words regarding the importance of these latest findings. This free event will take place on Monday, December 1st, from 3:00 – 4:00 p.m. at booth No. 5430.
• Free SaliMark OSCC Test Kit: Any dental practice owner who preregisters and creates a PeriRx online ordering account will receive one free SaliMark test kit in order to get familiar with the test, the protocol, and the lab results. Attendance at the Greater New York Dental Meeting is not mandatory, simply click here to register your practice and set up an account.*
* Not yet approved for sale in the state of New York. New York practice owners who register online will be kept on file and notified immediately when SaliMark is approved for sale and use in their state.
About SaliMark OSCC
Development of this simple-to-use, painless, and noninvasive test was based on the strong scientific foundation of NIH-funded research with initial discovery and prevalidation work conducted by Dr. David Wong of the University of California at Los Angeles. The SaliMark OSCC test also has the distinction of being the first of its kind assay in the world to aid in the identification and early detection of oral lesions at the highest risk for cancer. Recently, the SaliMark OSCC test underwent a PRoBE (prospective-specimen-collection, retrospective-blinded-evaluation) design study, which is the most rigorous biomarker validation available. In addition, PeriRx successfully completed a validation of the mRNA markers at the University of Michigan, Michigan State University, and the St. Johns Providence Health System in Detroit.
About PeriRx LLC
Based in Broomall, Pennsylvania, PeriRx LLC is a premier developer of breakthrough, noninvasive, oral diagnostic technology that will help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management.
The company was founded in 2008 to explore, innovate, and develop novel therapeutics or devices focused on the oral inflammatory/systemic connection. The PeriRx executive team consists of CEO and founder Stephen M. Swanick, an entrepreneur and experienced drug and device development professional; Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist.
PeriRx obtained its patented and patent-pending technologies from inventor Dr. David Wong’s firm RNAmeTRIX and the Regents of the University of California at Los Angeles. PeriRx and RNAmeTrix have ongoing agreements which ensure the continuing research and development necessary to advance product development from clinical trial, through regulatory approval, and into commercialization.